Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Purpose: To highlight the therapeutic promise of the incretin hormone glucagon‐like peptide‐1 (GLP‐1), the consequent rationale for therapies acting through GLP‐1‐mediated pathways in type 2 diabetes mellitus (T2DM), and the emerging clinical role of the dipeptidyl peptidase‐4 (DPP‐4) inhibitors and GLP‐1 receptor agonists. Data sources: The PubMed database was searched (using terms including incretins, GLP‐1, GIP, DPP‐4), along with recent ADA and EASD abstracts. Conclusions: Many traditional drugs used for T2DM fail to achieve and maintain glycemic control, and possess limitations such as risk for hypoglycemia and weight gain. GLP‐1 is a gut‐derived hormone that glucose‐dependently stimulates insulin secretion while simultaneously reducing gastric emptying and appetite. Other physiological actions of GLP‐1 may benefit the cardiovascular system and beta‐cell function. Recently developed drug therapies that mimic or prolong the action of this hormone, therefore, have great promise in the treatment of T2DM. Implications for practice: The GLP‐1 receptor agonists and DPP‐4 inhibitors are incretin‐based therapies that are now becoming established as effective therapies for T2DM to be used either as monotherapy or added to other antidiabetes drugs. They enable improvements to be made in glycemic control without weight gain, with a low risk for hypoglycemia, and with potential additional clinical benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 4×
“Indeed, intravenous infusion of native GLP-1 in people with T2DM was shown to increase insulin secretion, reduce glucagon secretion, and lower plasma glucose to normal levels within 4 h of commencing the infusion (Nauck et al., 1993b).”
BackgroundInfluentialDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 2×
“This effect might improve myocardial performance during ischemia or following myocardial infarction (Nikolaidis et al., 2004; Sokos et al., 2007), and might mitigate heart failure (Sokos, Nikolaidis, Mankad, Elahi & Shannon, 2006; Nyström, 2008); • protection against myocardial…”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857
New Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Cited by
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Seufert, J., & Gallwitz, B. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12251 · Cited by 156
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
Cui, J., Shang, A., Wang, W., & Chen, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118339 · Cited by 20
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
Retracted
Metadata
- Authors
- Wick, A., & Newlin, K.
- Venue
- Journal of the American Academy of Nurse Practitioners
- Publisher
- Wiley
- Published
- 2009-11
- Volume
- 21
- Issue
- s1
- Pages
- 623-630
- ISSN
- 1041-2972 (ISSN-L)
- 1745-7599
- OpenAlex
- W1984177371
- Cited by
- 13
- References
- 14
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1745-7599.2009.00455.x
- The paper
- Wick, A., & Newlin, K. (2009). Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes. Journal of the American Academy of Nurse Practitioners. https://doi.org/10.1111/j.1745-7599.2009.00455.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.